TSS
CTKB icon

Two Sigma Securities’s Cytek Biosciences CTKB Stock Holding History

Two Sigma Securities’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-23,379
Closed -$81.1K – 1568
2025
Q3 		$81.1K Buy
+23,379
New +$87.8K 0.01% 932

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Two Sigma Securities's CTKB Position: Q4 2025 in Review

Two Sigma Securities sold out of Cytek Biosciences (CTKB) in Q4 2025, closing a stake of 23,379 shares — an estimated $81.1K sold.

Two Sigma Securities first reported a position in CTKB in Q3 2025 and held it in 1 quarter. The position peaked at $81.1K in Q3 2025. 155 funds tracked by Wall St. Rank hold CTKB as of Q4 2025.

  • Two Sigma Securities reported no remaining Cytek Biosciences position as of Q4 2025 after selling out during the quarter.
  • Two Sigma Securities sold 23,379 Cytek Biosciences shares in Q4 2025, an estimated $81.1K.
  • Two Sigma Securities first reported a position in Cytek Biosciences in Q3 2025 and held it in 1 quarter.
  • Two Sigma Securities's Cytek Biosciences position peaked at $81.1K in Q3 2025.
  • 155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q4 2025.

Based on Two Sigma Securities's 13F filing for Q4 2025, filed 17 Feb 2026.